Skip to main content Accessibility help
×
Home

Evaluating the effectiveness of the clinical research radiographer undertaking the on-treatment review of clinical trial patients receiving radiotherapy for prostate cancer

  • Stacey Murray (a1), Terri M Gilleece (a1) and Paul H Shepherd (a1)

Abstract

Background

Radiotherapy clinical trials are at the forefront of modern-day prostate cancer patient management. Patients are reviewed during treatment by clinical oncologists or competent on-treatment review radiographers to minimise treatment toxicities. Clinical Research Radiographers (CRRs) routinely monitor and gather research data from patients participating in clinical trials.

Purpose

The aim of this article is to evaluate the effectiveness of the CRR undertaking the on-treatment review of clinical trial patients.

Method

An experienced CRR within the Northern Ireland Cancer Trials Network was supervised by a clinical oncologist to undertake the role of the on-treatment review of patients receiving radiotherapy for prostate cancer. The CRR explored published literature and compiled this written evaluation as part of their advanced practice learning.

Results

The supervising clinical oncologist verified, following the planned period of supervised practice and academic study, that the CRR was competent to fulfil the role. Evidence of the beneficial synergistic impact of co-joining the roles was experienced at first hand during the undertaking of supervised practice.

Conclusion

Co-joining the roles and responsibilities of the CRR and the on-treatment review radiographer enhanced the quality of care offered to the patients participating in clinical trials.

Copyright

Corresponding author

Author for correspondence: Terri M Gilleece, School of Health Sciences, Ulster University, Shore Road, Newtownabbey, BT37 0QB, Antrim, UK. E-mail: tm.gilleece@ulster.ac.uk

Footnotes

Hide All

Cite this article: Murray S, Gilleece TM, Shepherd PH. (2019) Evaluating the effectiveness of the clinical research radiographer undertaking the on-treatment review of clinical trial patients receiving radiotherapy for prostate cancer. Journal of Radiotherapy in Practice18: 123–126. doi: 10.1017/S1460396918000626

Footnotes

References

Hide All
1. National Institute for Health and Care Excellence. Prostate cancer: Diagnosis and Management. NICE clinical guideline CG175 developed by the National Collaborating Centre for Cancer. 2014. https://www.nice.org.uk/guidance/cg175. Accessed 7th October 2018.
2. Anandadas, C N, Clark, N W, Davidson, S E et al. Early prostate cancer—which treatment do men prefer and why? BJU Int 2011; 107 (11): 17621768.
3. Bauman, G, Rumble, R B, Chen, J, Loblaw, A, Warde, P. Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol 2012; 24 (7): 461473.
5. Ferlay, J, Soerjomataram, I, Dikshit, R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (5): E359E386.
6. ACORRN Research Radiographer Working Party, Russell, W, McNair, HA et al. Gap analysis of role definition and training needs for Therapeutic Research Radiographers in the UK. Br J Radiol 2007; 80: 693701.
7. The Department of Health. The National Health Service Plan, a plan for investment, a plan for reform. 2000. https://navigator.health.org.uk/content/nhs-plan-plan-investment-plan-reform-2000. Accessed 7th October 2018.
8. The Department of Health, The NHS Cancer Plan and the new NHS: providing a patient centred service. 2004. http://www.wales.nhs.uk/technologymls/cymraeg/resources/pdf/cancer_nsf.pdf. Accessed 7th October 2018.
9. Cancer Research UK and NHS England. Vision for Radiotherapy 2014–2024. March 2014. https://www.cancerresearchuk.org/sites/default/files/policy_feb2014_radiotherapy_vision2014-2024_final.pdf. Accessed 7th October 2018.
10. Lee, L. The role of the “on treatment” review radiographer: what are the requirements? J Radiother Pract 2008; 7: 113131.
11. Colyer, H. The role of the radiotherapy treatment review radiographer. Radiography 2000; 6: 253260.
12. Ellis, T, Ashmore, L, Bray, D. Multidisciplinary radiographer-led review clinics—an example of implementation. J Radiother Pract 2006; 5: 8795.
13. Morote, J, Maldonado, X, Morales-Bárrera, R. Prostate cancer. Clinical Medicine 2016; 146 (3): 121127.
14. Kalbasi, A, Li, J, Berman, A T et al. Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA Oncol. 2015; 1: 897906.
15. Kim, MM, Hoffman, KE, Levy, LB et al. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J 2012; 18 (1): 18.
16. Coyne, K, Zhou, Z, Thompson, C, Versi, E. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 2003; 92 (7): 731735.
17. Schaake, W, Wiegman, M E, de Groot, M et al. The impact of gastrointestinal and genitourinary toxicity on health related quality of life among irradiated prostate cancer patients. Radiother Oncol 2014; 110: 284290.
18. Widmark, A, Klepp, O, Solberg, A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301308.
19. Kumar, R J, Barqawi, A, Crawford, E D. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 2005; 7 (Suppl 5): S47S443.
20. Boberg, EW, Gustafson, D H, Hawkins, R P et al. Assessing the unmet information, support and care delivery needs of men with prostate cancer. Patient Educ Couns 2003; 49 (3): 233242.
21. Ormerod, AM, Jessop, AJ. An evaluation of support of patients with prostate cancer during and beyond radiotherapy treatment. A local perspective on future provision. J Radiother Pract 2015; 14 (4): 370377.
22. Evans, C M, Burnet, N G, Hall, E, Huddart, R A, Nutting, C M, Coles, C E. The Radiotherapy clinical trial research landscape in the UK between 2004 and 2013: A cross-sectional analysis. Clin Oncol 2015; 27 (9): 491494.
23. Dearnaley, D, Syndikus, I, Mossop, H et al. 8LBA 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP trial investigators group. Eur J Cancer 2015; 51 (3): S712.
24. Van Dongen, AJ. Good clinical practice, a transparent way of life. A review. Comput Med Imaging Graph 2001; 25 (2): 213216.
25. White, P, McKay, JC. Guidelines and legal requirements, which inform role expansion in radiography. Radiography 2002; 8 (2): 7178.
26. Høyer, M, Muren, PL, Glimelius, B. The evolution of radiotherapy techniques in the management of prostate cancer. Acta Oncologica 2015; 54 (6): 821824.
27. Chin, S, Hayden, AJ, Gebski, V, Cross, S, Turner, S L. Long term patient reported urinary function following external beam radiotherapy for prostate cancer. Clin Oncol 2017; 29 (7): 421428.
28. Crowther, K, Shepherd, PH, Shiels, P, Jain, S, Mitchell, D. A pilot study of patient reported outcomes evaluating treatment related symptoms and quality of life for men receiving high dose rate brAchytherapy combined with hypo-fractionated radiotherapy or hypo-fractioNated radiotherapy alone for the treatment of localised prostate cancer. tipsRO. 2018; In Press.
29. The Society and College of Radiographers. The prostate/urology specialist cancer workforce: provision of specialist therapeutic radiographers in the treatment and care of men with prostate cancer. 2015. https://www.sor.org/learning/document-library/prostateurology-specialist-cancer-workforce-provision-specialist-therapeutic-radiographers-treatment. Accessed 7th October 2018.
30. Probst, H, Griffiths, S. Job satisfaction of therapy radiographers in the UK: results of a phase I qualitative study. Radiography 2009; 15 (2): 146157.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed